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ABSTRACT

Previously, it was shown that SJL/J mice given Ig-PLPI in saline at the neonatal
stage were resistant to the induction of Experimental Allergic Encephalitomyelitis (EAE)
later in life (21 ). Contributing to this resistance were T cells which displayed a unique
phenotype consisting of IFN-y mediated anergy in the spleen, and Th2 deviation in the
lymph nodes (21 ). The objective of these studies was to investigate whether differences
in the T cell repertoires between the lymph node and spleen contributed to this organ
specific modulation of disease. This was achieved by immortalizing PLP 1 specific T cell
hybridomas from both lymphoid organs and analyzing their T cell receptors.
Specifically, the T cell receptor beta chains were analyzed for their variable (V), diversity
(D), and joining (J) gene segment usage to see whether or not a particular gene segment

may be involved in the responses. Additionally, the CDR3 regions were analyzed by
their lengths and amino acid composition to gain further insight about the antigen
binding site. It was found that there was no restriction in the V, D, or J gene usage, in
either the spleen or lymph node T cells. However, in analyzing the CDR3 region of the
TCRs, a Glycine-Glycine motif was found in the cells from the lymph node. The splenic
T cells did not contain this motif in their CDR3 regions. Therefore, it can be postulated
that this G1y-G1y motif creates a structural change in the TCRs from the lymph node and
this difference may contribute to a different binding affinity of the TCR toward the
peptide and thus lead to the organ specific responses previously seen.
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I. INTRODUCTION & REVIEW OF THE LITERATURE

T Cell Activation

The immune response functions to fight foreign invaders, or antigens, in the body.
T cells are vital players involved in this defense. T cells recognize antigens via a
membrane bound receptor, the T cell receptor (TCR). The TCR can only recognize
antigens in the form of short peptide fragments attached to major histocompatibility
compJex (MHC) proteins on the surface ofother cells. These other cells which present
peptide-MHC complexes on their surface are generically termed antigen presenting cells
( APCs). Dendritic cells� macrophages� and B cells are the most common cell types�
which present antigens to T cells. T cells can be categorized into two types, cytolytic T
lymphocytes (CTL) which express the coreceptor CDS, and helper T cells (Th) which
express the coreceptor CD4. Accordingly, there are two major pathways for antigen
presentation to T cells, know as the endogeneous and exogeneous pathway, respectively
(1).
In the endogenous pathway proteins synthesized within the APC are processed
into peptide fragments by an enzyme complex called the proteosome. The peptides are

transported to the endoplasmic reticulum (ER) where they bind to MHC class I
molecules. The peptide-W:IC I complex migrates to the Golgi apparatus, enters an

endocytic vesicle, and is eventually translocated to the cell surface where it can be
recognized by antigen specific CDS+ T cells ( 1).
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In the exogenous pathway extracellular proteins are internalized by APCs and
processed within acidic vacuoles into short peptide fragments. Meanwhile, MHC class II
molecules are synthesized in the ER, transported to the Golgi, and contained in endocytic
vesicles. The two vesicles fuse together and the peptide is loaded onto the MHC class II
molecules. The peptide-WIC II complex is trans1ocated to the cell surface where it can
be recognized by antigen specific CD4+ T cells. Therefore, the exogeneous pathway
yields MHC class II restricted CD4+ helper T cells (1). For the remainder of this
discussion, we will be focusing on these CD4+ Th cells.
After the T cell receptor engages the peptide- MHC complex, a signal known as
signal 1 is generated (Figure 1 ). Signal 1 by itself is not sufficient to drive activation of
the T cell. A second signal is needed which involves engagement of costimulatory
molecules, such as B7.1 on APCs, and CD28 on T cells. Once the two signals are
generated, the T cell will become activated and secrete protein hormones called cytokines
which will act on the T cell itself as well as on other cells to promote immune responses.
Helper T cells can be classified into two subsets, Th l or Th2, based on the cytokines that
they secrete. Th 1 type cells are characterized by their production of proinflammatmy
cytokines such as IL-2, and IFN--y, whereas Th2's produce non-inflammatory cytokines
like IL-4 or IL-10 (1 ).

The T Cell Receptor Complex

The T cell receptor complex is composed of several membrane-bound proteins which act
together to recognize the peptide-MHC complex and subsequently transmit signals to the

2

MHC class II

I

Peptide
TCR

CD4

/

'

B7.1

Figure 1: T Cell Activation:

Helper T cells recognize antigens in the context of peptides bound to MHC class II
molecules. With the aid of the coreceptor CD4, the TCR engages the peptide-MI-IC
complex and a first signal is induced. Upon engagement of costimulatory molecules
(B7.1 and CD28), a second signal is generated and the T cell becomes activated and
secretes cytokines.
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intracellular milieu (Figure 2). The antigen binding unit ofthe receptor consists ofa
heterodimer oftwo transmembrane polypeptide chains, the a and f3 chains, covalently
linked by disulfide bonds. The a and f3 chains each contain two immunoglobulin-like
domains, the variable (V) and constant (C) domains, as well as a transmembrane domain
and a cytoplasmic tail. The signaling unit or CD3 complex consists of 3 structurally
homologous proteins, y,'6, and E and a homodimer of a chain known as the zeta (�) chain.
The CD3 and zeta (�) proteins are noncovalently linked to the af3 heterodimer and, while
they do not play any role in antigen binding, they do aid in signal transduction within the
T cell (1 ).
Helper T cells express the coreceptor CD4 which is a monomer containing four
lg-like domains, a transmembrane domain and a cytoplasmic tail. CD4 binds to class II
MHC molecules and is a necessary component in transducing signals which activate the
T cell (1).
The genes encoding the a. and � chains are located on two separate loci and
contain multiple gene segments (Figure 3). The a chain ofthe TCR encompasses
variable and constant regions. The variable region, which participates in the formation of
the antigen combining site, is encoded by the variable (V), and joining (J), gene
segments. The (3 chain also comprises variable and constant regions and is encoded by
variable (V), diversity (D) and joining (J) segments. The V, D, and J segments are
assembled by somatic recombination, which generates many different antigen receptors
and therefore a large and diverse T lymphocyte repertoire. In one person there are many
clonally derived lymphocytes, with each clone coming from one precursor and
4
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Figure 2 : Schematic Representation of the T Cell Receptor (TCR)
Complex

The TCR complex is composed of an aJ3 heterodimer which makes up the antigen
receptor, and the CD3 and � proteins which aid in signal transduction.
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Figure 3: Schematic Representation of the TCR a and � Genes

The variable regions of the TCR are encoded by the variable (V), diversity (D)('3 chain
only), and joining (J) gene segments. The constant regions are encoded by the constant
(C), transmembrane (TM), and cytoplasmic tail gene segments. Three complementarity
determining regions ( CDRs) are indicated by the dashed boxes.
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recognizing a distinct antigenic determinant. This generates a repertoire ofaround 109
different specificities ( 1).
The variability between the different T cell receptors is concentrated in the amino
acid sequences within the variable regions of both the a and p chains. Specifically, there
are short hypervariable stretches of amino acid residues that were defined as
complementarity determining regions (CDRs) because they provide conformational
surfaces that form contact with the antigen. There are three CDRs in each a and � chain,
which assume loop structures and come together to form the 3-D structure of the antigen
combining site. The greatest sequence variability is contained within the third
hypervariable region, or CDR3. Therefore, the CDR3 is the most important portion of
the TCR in determining the specificity ofantigen binding (10). In fact, analysis ofthe
nucleotide sequence ofCDR has evolved as a technology to monitor antigen specificity
ofthe TCR.

Autoimmunity

During T cell development in the thymus, T cells which bind self-antigens with high
affinity are deleted by a process called negative selection. This is to ensure that the
immune system is self-tolerant, or umesponsive to it's own (self) antigens. However, this
process is imperfect and some self-reactive T cells may escape the thymus and enter the
periphery. Reactivation of these cells can lead to inflammatory reaction and tissue injury
that culminate into autoimmune diseases. In particular, activation of self-reactive Th]
cells leads to over-production ofinflammatory cytokines resulting in tissue damage.
Humans multiple sclerosis (MS)� insulin-dependent diabetes mellitus (IDDM), and
7

rheumatoid arthritis (RA) are examples of autoimmune diseases. Animal models of these
diseases have been developed which have allowed for more intensive investigations into
the mechanisms of these diseases ( 1 ) (25).

Experimental Allergic Encephalitomyelitis (EAE)

EAE is an animal model for the human disease multiple sclerosis (MS) and is
characterized by demylelination and inflammation within the central nervous system
(CNS) (25). CD4+ T helper cells become autoaggressive against self-myelin antigens
found in the CNS (32). These myelin antigens include proteolipid protein (PLP), myelin
basic protein (MBP), myelin oligodendroglial protein (MOG) and myelin associated
glycoprotein (MAG)(32). When these proteins, or their corresponding encephalitogenic
peptides are injected into mice in complete Freund's adjuvant (CFA), EAE develops (32).
This discussion will be focused on the encephalitogenic peptide corresponding to
residues 1 39- 1 5 1 of proteolipid protein, herein referred to as PLP 1. Mice of the SJL/J
strain are genetically susceptible to EAE and can be induced for disease when injected
with PLP 1 peptide in CFA, or by adoptive transfer of T cell lines specific for PLP 1 ( 15).
In these studies, we wiJJ be investigating mechanisms of neonatal tolerance using this
EAE model system.

Neonatal Tolerance

The neonatal period is considered to be a short window of time in which initial
encounter with an antigen instructs the immune system to tolerate the antigen by
displaying no aggressivity toward it during subsequent encounters ( 5). This concept has
8

been exploited using animal model systems in which antigens given at the neonatal stage
resulted in a tolerant response upon reexposure to the antigen (22). There are ongoing
investigations into the mechanisms responsible for neonatal tolerance in different
experimental systems. Early investigations attributed this immunological
unresponsiveness to development of suppressor cells that display do\\in regulatory
function on target T cells (2). Also, T cell anergy (13), deletion and/or inactivation (9)
were considered as plausible mechanism for neonatal tolerance. Surprisingly, however,
recent experiments have indicated that exposure to antigen at the neonatal stage primes
rather than ablates T cells leading to organ specific responses involving immune
deviation (8) (22) (21) (18).
In standard experimental models of neonatal tolerance in mice, the typical tolerization
protocol involves intraperitoneal injection of antigen, in the form of a peptide emulsified
in incomplete freunds adjuvant (IFA), within 24 hours of birth (6) (8) (22). Once the
mouse reaches adulthood, after around 6-8 weeks, it is immunized with a subcutaneous
injection of the peptide in CFA (8) (22) (6). In this paper, we will be discussing a novel
form of neonatal tolerization which utilizes an lg-chimera as the tolerizing molecule
rather than standard peptide administration (21 ).

lg-chimeras

A novel system of antigen delivery has been established in which immunoglobulin
(Ig) molecules have been genetically engineered to contain antigenic epitopes (30). These
chimeras have been shown to effectively deliver the peptides to T cells via APCs and
generate immune responses in vivo (3 1 ) (17). lg-chimeras have been shown to have
9

many advantages over standard peptide administration (31 ). Igs are internalized via Fe
receptors into APCs where the incorporated peptides are processed and liberated within
the endosomal compartment, and can access newly synthesized MHC class II molecules,
whereas exogenous peptides must displace existing peptides from previously formed
peptide-MHC complexes on the cell surface. In fact, it has been shoMt that peptides
contained within lg-chimeras are presented 100-1000 times more efficiently than peptides
alone (3 1 ). Another obstacle in the administration of peptides in vivo is that they require
the use of adjuvants in order to generate an effective immune response. This can be
counterproductive since adjuvants have been shown to have harmful side effects, such as
the induction of oil-induced arthritis, when administered in vivo (24 ). Adjuvants are
thought to contribute to the slow release of the antigen when administered in vivo and to
induce cytokine production necessary for T cell differentiation. Since Igs have long half
lives, can induce cytokine secretion by binding to Fe receptors (27) ( 1 4), and are
autologous molecules devoid of side effects, the use of adjuvants can be circumvented
using this novel peptide delivery system (21 ). Thus, lg-chimeras have provided an
effective strategy for vaccine development (31) as well as induction for neonatal
tolerance (21 ).

Neonatal tolerization with Ig-PLPl
An lg-chimera, referred to as Ig-PLPl, was generated via insertion of proteolipid
protein 1 (PLPl ) peptide into the CDR3 region of the heavy chain of a self
immunoglobulin molecule (Figure 4) ( 17). A counterpart molecule, Ig-W was also
previously generated which is the parental molecule not containing any peptide insertion
10

into its CDR3 region (Figure 4) (30). Ig-PLP l was proven effective by showing an
increased peptide presentation by 1 00-fold in comparison with exogenous PLPl ( 1 7). In
addition, Ig-PLP 1 was found to induce PLP I-specific T cell responses in the spleen and
lymph nodes that were of Thl

type

and produced both IL-2 and IFN-y ( 1 7) ( 1 6).

Furthermore, Ig-PLPl has been successful as a tolerizing molecule in neonates leading to
the prevention of autoimmunity (21 ). Indeed, administration of Ig-PLPl into one day
old SJL/J mice in saline instead of IFA lead to resistance against EAE induction. In
contrast, littermates given lg-W instead of lg-PLPl developed severe signs of paralysis
when induced for EAE with PLP l peptide in CFA (2 1).
The resistance against EAE was consistent as the daily scores based on clinical
symptoms of paralysis were reduced for a long period of time. Typical scoring of EAE is
as follows: 0 = no clinical symptoms, 1 = loss of tail tone, 2 = hindlimb weakness, 3 =
hindlimb paralysis, 4 = forelimb paralysis, 5 = moribund or death. According to this
scale, mice tolerized with Ig-PLP l showed a mean maximal disease severity of2.7 ± 0.5
and 0% mortality rate, whereas mice given lg-W showed a 4.2 ± 0.9 mean maximal
disease severity and a mortality rate of 40%. In addition, Ig-PLPI tolerized mice showed
a delay of disease onset, and did not display any relapses while the control animals had
norma1 disease onset and developed relapses. Therefore, mice to1erized with Ig-PLP 1 at
the neonatal stage resist induction of EAE during adulthood (2 1 ).
In order to investigate the mechanisms underlying this form of tolerization,
proliferative and cytokine responses were analyzed. Mice were given lg-PLP l in saline
on the day of birth, then immunized with PLP l peptide in CFA at the age of 7 weeks. Ten
days later, the mice were sacrificed and their lymph nodes and spleens were taken. Single
11
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PLP 139-151
(HSLGKWLGHP)

Figure 4: Schematic Diagram of lg-Chimeras

The lg-chimera Ig-PLP 1 was generated via insertion of residues 139-1 5 1 of proteolipid
protein (PLPl peptide) into the CDR3 region of the heavy chain of a self
immunoglobulin molecule ( 1 7). lg-W is the parental molecule which does not contain
any peptide insertion (30).
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cell suspensions were made from both organs and the cells were incubated with either the
stimulatory PLP l peptide or the negative control peptide, PLP2 (residues 178-191 of
PLP). Proliferation was measured by thymidine incorporation. The results showed that
mice tolerized with Ig-PLP 1 developed T cell proliferative responses to PLP 1 peptide in
the lymph node but not in the spleen, whereas mice to1erized with the control Ig-W
developed proliferative responses in both lymphoid organs. Neither group showed
proliferative responses toward the negative control PLP2 peptide. Therefore, tolerization
with Ig-PLP 1 at the neonatal stage leads to a proliferative response in the lymph node but
unresponsiveness in the spleen upon challenge with PLPI peptide. This finding was the
first indication of an organ-specific modulation of the T cells in lg-PLP 1 tolerized mice
(21 ).
Next, the cytokine profile in the lymph nodes and spleen of these animals was
analyzed by ELISPOT and ELISA, respectively. The results indicated that lymph node T
cells from Ig-W tolerized mice produced IL-2, but not IL-4 or IFN-y when stimulated
with PLPl peptide. However, T cells from Ig-PLPl tolerized mice produced IL-4 but not
IL-2 or IFN-y. Therefore, mice tolerized with Ig-PLP I exhibited a deviated cytokine
profile in the lymph nodes which switched from a Th 1 to a Th2 phenotype (21 ).
In the spleen, T cells from the Ig-W tolerized mice produced both IL-2 and IFN-y.
However, T cells from the Ig-PLPl tolerized mice, which were previously shown to be
nonproliferative, produced IL-2 but not IFN-y. IL-2 is an autocrine growth factor and its
production indicates that the T cells from Ig-PLPl tolerized mice were not deleted even
though proliferation was diminished. Therefore, it was hypothesized that the splenic
13

nonproliferative response may be due to the absence of IFN-y. In response to this
question, exogeneous IFN-y or the IFN-y inducing cytokine IL-1 2 was added to the
splenic cell cultures and the proliferative response was remeasured. Surprisingly, the
addition ofIFN-y or TI....- 1 2 restored proliferation. This restoration was antigen specific
since addition of exogeneous cytokine did not restore proliferation when in vitro
stimulation was carried out with PLP2 peptide. Thus, it was concluded that splenic cells
from Ig-PLPI to1erized mice were not de1eted but rather anergized. This was considered
a new form of anergy characterized by the loss of IFN-y. Therefore, Ig-PLPl tolerized
mice exhibit a novel form ofIFN-y dependent anergy (2 1 ).

Rationale and Research Obiectives

Ig-PLP I tolerized mice are resistant to EAE and exhibit an organ specific
modulation of the disease characterized by immune deviation in the lymph node and a
novel form ofIFN-y mediated splenic anergy. Organ specific responses in neonata1ly
tolerized mice have been observed before, (8) (22). However, there are still many
questions regarding the biased immune responses and the_organ specific regulation that
develops in the neonates. It has previously been suggested that down regulation of the
lymph node homing receptor, L-selectin on memory cells, redirect lymphocytes to
migrate to the spleen (8). Others have suggested that the T cell repertoires involved may
contribute to the various mechanisms.
Recent work has shown that mice injected with hen egg lysozyme 1 06- 1 16
determinant

(HEL 1 06-I I6)

at the neonatal stage generated responses, upon reexposure to
14

the peptide, which involved biased Vf3 gene usage (20). Accordingly, it has been shown
that adult mice immunized with HEL106-1 16 mount a response that is dominated by T cells
utilizing Vf38.2 variable and Jf3 1 .5 joining segments to form their heavy chain variable
region gene (9). This observation along with structure analysis of the CD3 region has led
to the conclusion that the HEL response in adult mice derives from a public clone
restricted to a specific CDR3 region (9). When neonatal mice were tolerized with HEL in
IFA, then immunized as adults with HEL106-1 16 in CFA, a proliferative response was seen
in the spleen but not in the lymph node (20). When the splenic cells were examined, it
was found that the proliferative response did not come from the public Vf38.2 Jf3 1 .5 T
cells, but rather came from different antigen specific cells (20). Additionally, these cells
showed a deviated cytokine profile, which was of the Th2 type (20). Therefore, it was
concluded that the V'38.2 J'3 1.5 public repertoire was deleted and the remaining antigen
specific repertoire exhibited immune deviation (20). Additionally, it was specuJated that
the reason the V'38.2 J'3 1.5 public repertoire was more susceptible to anergy was due to
the avidity of this TCR- HEL-MHC interaction (20). It was also suggested that these
cells died by apoptosis, since it was known before that IL-2 producing Thl cells are more
susceptible to apoptosis (20) (28). They also implied that the Th2 nature of the remaining
cells was due to a relatively weak affinity of the TCRs for the HEL-MHC complex (20).
Therefore, since the T cell responses in mice recipient of lg-PLPl at the neonatal
period and challenged with PLP I peptide at the age of 7 weeks develped deviated T cells
in the lymph node and anergic Th 1 cells in the spleen we sought to investigate whether
bias in the T cell repertoire is responsible for this organ specific regulation of the
15

responses. Specifically, we would like to know whether or not the organ specific
responses are due to different TCR repertoires being present within the different organs.
Thus, the questions we will be asking are as follows: What contributions do the T cell
repertoire make in the organ specific mechanisms of tolerance previously seen? Are the
repertoires within and between the two organs homogeneous or heterogeneous and does
this contribute to the anergy/ immune deviation? If differences are seen between the two
organs, could this be due to a stronger or weaker affinity to bind the antigen? Are there
any mutations in the CDR3 regions? Could there be a common CDR3 region in the
TCRs ofthe splenic T cells, which contributes to their anergy possibly due to a higher
binding affinity? Do the deviated lymph node cells contain a TCR with a lower binding
affinity? These questions will be addressed by first identifying the T cell repertoires
within the two organs using mAbs and DNA primers specific for the various variable
regions ofthe beta chain (Vf3) ofthe TCR, then sequence comparisons will be done for
the various CDR3 regions.
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II. MATERIALS AND METHODS

Peptides

PLP I (HSLGKWLGHPDKF), is an encephalitogenic peptide which corresponds to
amino acid residues 1 39-1 51 of proteolipid protein. PLP2 peptide
(NTWTTCQSIAFPSK) is also an encephalitogenic peptide and corresponds to residues
178-179 of proteolipid protein. The peptides were purchased from Research Genetics,
Inc. (HuntsviJJe, AL) and were HPLC purified to >90% purity.

lg- chimeras

The chimeras referred to as Ig-PLP I and Ig-W were generated previously (17) (30).
Briefly, the 5 . 5-kb DNA fragment encoding the heavy chain variable region of the 91A3
antibody to arsonate was used in a polymerase chain reaction (PCR) mutagenesis to
replace the D segment with a nucleotide sequence encoding residues 139-1 5 1 of
proteolipid protein. The mutated Vh gene was sequenced to ensure peptide insertion into
the correct reading frame and subcloned into a vector (PSV2-gpt-Cy2b) in front of exons
coding for the Ig constant region ( 1 7). The plasmid was co-transfected into the non-Ig
producing B myeloma cells SP2/0 along with an expression vector carrying the parental
91A3 light chain (pSV2-neo-9 1A3L) ( 1 7). The chimera referred to as Ig-W is the
parental lg which does not contain any insertion into it's CDR3 region is used throughout
the experiments as a negative control (30). Transfected cells were grown up in large
scale cultures of DMEM containing I 0% iron-enriched calf serum (Intergen, Purchase,
NY).
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Affinity Chromatography

The secreted lg-chimeras were affinity purified on columns made of rat anti-mouse K
chain coupled to CNBr-activated Sepharose 4B (Amersham Pharmacia Biotech,
Piscataway, NJ). Briefly, one liter of cell supernatant was passed per column. Columns
were washed with PBS, and the lg-chimeras were eluted with 0. 1 M Sodium Citrate pH
2.6. The eluted fractions were read on a spectrophotometer at an optical density (OD) of
280. Fractions with an OD280 > 0.05 were kept and neutralized with IM K2HP04 , pH 8,
then dialyzed overnight at 4°C against PBS. Ig-PLPl and Ig-W chimeras were purified
on separate columns to avoid cross contamination. Chimeras were subsequently
concentrated using collodion membranes (Schleicher & Schuell, Keene, NH) to ~ 1
mg/ml.

Mice

All mice used were of the SJL/J strain and purchased from Harlan Sprague Dawley
(Frederick, MD). SJL/J mice are genetically susceptible to BAE. Mice were housed in
the animal care facility and experiments were conducted according to the guidelines of
the institutional animal care committee.

Neonatal tolerance regimen

On the day of their birth, SJL/J mice were injected intra-peritoneally (i. p. ) with 100 µg of
either the Ig-PLPl chimera or Ig-W chimera diluted in phosphate buffer saline (PBS).
After six to eight weeks when the mice reached adulthood, they were immunized with
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1 00 µg PLPl peptide emulsified in complete freunds adjuvant (CFA) and PBS ( 1 : 1 v/v).
Injections were made subcutaneously into the footpads and the base of the limbs for a
total injection volume of 200 µI per mouse. Ten days later, the mice were euthanized by
cervical dislocation and the spleens and draining lymph nodes (axillary, inguinal,
popliteal, and sacral) were removed for the generation of T cell lines.
Generation of T Cell lines
The spleens and lymph nodes of mice that were given Ig-PLP I on the day of birth and
injected with PLPl peptide in CFA at the age of 7 weeks were removed and the cells
were resuspended at 5 x 1 06/ml in HT-2 media (DMEM supplemented with fetal calf
serum, L-glutamine, sodium pyruvate, gentamycin sulfate and 2-mercaptoethanol.
Subsequently, the cells were stimulated with PLP l peptide at l 5µg/m1 and incubated at
37° C and 7% CO2 . The cells from the spleen were also given rIL-12 at l0u/ml and anti
IL-4 at 10 µg/ml. After 5 to 7 days of stimulation the peptide is washed off and the cells
were resuspended in fresh media containing 3% T-stim (Fisher Scientific, Pittsburg, PA)
without peptide and rested for 7 to 1 0 days. The cells were again restimu1ated with 2 x
106 syngeneic APCs pulsed with 15 µg/ml PLPl, in the presence of 3% T-stim and rested
for 7 to 1 0 days. The restimulationlresting cycle is repeated unti1 sufficient number of
cells was generated. This population of cells is referred to as T cell line.

Antigen Presenting Cells (APCs)
APCs used in all experiments were from the spleens of SJL/J mice and prepared
according to standard protocol. Briefly, SJL/J mice were sacrificed by cervical
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dislocation and their spleens removed. The spleens were evacuated, and brought to a
single cell suspension in DMEM media (Fisher Scientific, Pittsburg, PA). The
splenocytes were irradiated at 50 kV, IO mAmps for 7 minutes. The cells were then
centrifuged at 1600 rpm and 4 °C for 10 minutes, and resuspended at 10 x 106/ml in HT-2
Media (Fisher Scientific, Pittsburg, PA).

Generation of T Cell Hybridomas
In order to immortalize the T cells, the lines were fused with BWl 1 00, a murine T cell
thymoma line that is deficient for the alpha and beta chains of the T cell receptor.
Specifically, the T cells and their fusion partner were harvested and counted, then spun
down separately in a centrifuge at 1600 rpm at 4 ° C for 6 minutes. The cells were
washed with 20 ml plain DMEM media (Fisher Scientific, Pittsburg, PA) then spun again
at 1600 rpm at 4 °C for 6 minutes. The cells were then resuspended separately at
1 x 1 06/ml, then 10 ml of each were mixed together ( 1 : 1 ratio) and spun down at 1 000 rpm
and 4 ° C for 10 minutes. The pellet was resuspended in 1 ml of pre-warmed 37 ° C
polyethylene glycol (PEG 4000) (Fisher Scientific, Pittsburg, PA) over a period of
1 minute while slowly turning the tube in hand. The tube was held for 4 5 seconds to
ensure membrane fusion, then 1 0 ml of pre-warmed DMEM was added to the tube, the
first ml over 30 seconds and the remaining 9 ml over the next 30 seconds. The cells were
spun again at 1600 rpm at room temperature for 1 O minutes. The pellet was resuspended
in 10 ml of pre-warmed fusion media (HT-2 media + essential and nonessential amino
acids) (Fisher Scientific, Pittsburg, PA). The cells were aliquoted in a 96 well flat20

bottom plate at 1 00 µl per well and incubated at 37°C and 7% CO2 for 24 hours.
Following incubation, 100 µl of a selective media, 1 X HA (fusion media containing IX
concentration of hypoxanthine and azaserine (Sigma) was added to each well. BWl 100
cells alone do not contain the enzyme required to survive in this media, but the T cells do.
However, T cells will die of neglect when kept in media alone without antigen.
Therefore, only fused cells (hybridomas) are able to survive in this media. Plates were
kept at 37°C and 7% CO2 until the hybridomas had grown to confluency.

Screening of hybridomas by ELISA

T Cell Hybridomas (50,000/well) were incubated with APCs (500,000/well), and either
the stimulator peptide, PLP l , or control peptide, PLP2, ( 1 5 µg/ml) for 24 hours at 37 ° C
and 7% CO2. Hybridomas generated from the lymph node were screened for the
production of IL-4 whereas those generated from the spleen were tested for IFN-y
production. Briefly, 96 well flat bottom plates were coated with 50µ1/weII of capture
antibody: either rat anti-mouse IL-4, 1 lBl 1 , or rat anti-mouse IFN-y, R4-6A2, (ATCC,
Manassas, VA) at 2µg/ml diluted in IM NaHCO3 . Plates containing capture antibodies
were incubated overnight at 4 ° C then washed 3 times with PBS-Tween (0. 5 % Tween
20, Fisher Scientific, Pittsburg, PA?). Plates were then blocked with PBS-3% Bovine
Serum Albumin (BSA) (Boehringer Mannheim) and incubated for 2 hours at room
temperature, then washed again with PBS-3% BSA three times. The 96 well round
bottom plates from the T Cell Activation Assay were spun down at1 600 rpm and 4 °C for
I O minutes and then I 00 µl of supernatant was transferred to the coated flat-bottom
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plates. Cytokine standards (either recombinant IL-4 or IFN-y, PharMingen, San Diego,
CA) were added at this time also, at 4, 2, 1, 0.5, 0.25, 0. 125, 0.062, 0.032, 0.0 16 ng/ml
diluted in PBS-3% BSA and the plates were incubated overnight at 4 °C. Plates were
then washed again with PBSffween three times. Biotinylated anti-cytokine antibodies,
rat anti-mouse IL-4, BVD6-24G2, or rat anti-mouse IFN-y, XMGl.2, (PharMingen, San
Diego, CA) were diluted to 1µg/ml in PBS-3% BSA and added to the plates at 100
µI/well. Plates were incubated at room temperature for 45 minutes, and then were
washed with PBS/Tween. 100 µI/well ofAvidin-peroxidase was added to each well at
1 :400 dilution in PBS- 3% BSA. Incubation was 30 minutes at room temperature then
washing was repeated. A colormetric developing solution, ABTS, ( 1 50 mg ABTS,
(Sigma Chemical Co., St. Louis, MO) diluted in 500 ml 0. 1 M citric acid pH 4. 35, + 1 0
µ1 H202/ 10 ml) was added at 100 µ1/well. Plates were incubated for 20 minutes, then the
0D405

was measured on a SpectraMAX 340 counter using Spectra MAX PRO version

1.2.0 software (Molecular Devices, Sunnyvale, CA). The graded amounts of
recombinant mouse IL-4 and IFN-y included in all experiments were used in order to
construct standard curves. The concentration of cytokines in the culture supernatants was
estimated by extrapolation from the linear portion of the standard curve.

Cloning and Screening of Clones
Hybridoma cells were harvested, spun down at I 600 rpm and 4 °C, counted, and
resuspended at 1 X 10 6 cells/ ml. Serial dilutions were made until a final concentration
of 1 cell per I 00 µl was reached. I 00 µl of cells were plated in a 96-well flat bottom
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plate for a final concentration of 1 cell per well. Individual wells were screened via
ELISA as described previously.

Flow cytometry analyses

Hybridoma clones were stained with a panel of FITC labeled mAbs specific for different
variable regions of the T cell receptor beta chain. The panel included the following:
V�2, V�3, VP4, V�S.1/5.2, Vp6, VP7, V�8. l/8.2, vp8.3, V�9, V�lO, vp1 1, vp12,
Vf3 1 3, Vf3 1 4, Vf3 1 7. Hybridoma clones were harvested, spun down at 1 600 rpm and 4 °C,
counted, and resuspended at 1 X 1 0 6 cells/ ml in PBS. One ml of cells ( 1 X 10 6 cells)
was aliquoted per rnicrofuge tube and the cells were spun again at 8000 rpm, for 4
minutes. The supernatant was decanted and the pellet was resuspended in 1 ml of
washing buffer (PBS/BSA/Azide). One FITC labeleled Vf3 mAb was added to each tube
(20 µl/ 106 cells) along with 1 µl PE labeled anti-CD4. Controls consisted of PE labeled
anti-CD3 and FITC labeled anti-beta chain, as well as FITC-anti-CD4 and PE-anti-CD3,
to ensure that the a.� TCR was present. The tubes containing the cells and staining
antibodies were incubated for thirty minutes on ice. The cells were then spun at 8000
rpm for 4 minutes, supernatant decanted, then resuspended in 0. 5 ml washing buffer. A
fixing solution (2% formaldehyde) was then added at 0.5 ml per tube and the cells were
incubated at room temperature for 20 minutes. Tubes were spun again, supernatant
decanted, and pellet resuspended in 1 ml PBS then transferred to 5 ml snap-cap tubes
(Fisher Scientific, Pittsburg, PA). The samples were analyzed on a F ACScan flow
cytometer (Becton Dickinson, Mountain View, CA) using CellQuest software (Becton
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Dickinson). All fluorescent labeled mAbs used for flow cytometcy were purchased from
PharMingen (San Diego, CA).

mRNA extraction

Messenger RNA was extracted from the hybridoma clones using the µMACS mRNA
isolation kit from Miltenyi Biotec (Auburn, CA) according to their protocol and all
buffers and reagents were provided with the kit. 1 X 1 07 cells were harvested and
centrifuged at 1 600 rpm and 4 °C in a 1 5 ml tube. The supernatant was decanted and 1 ml
of Lysis/Binding buffer was added. The cells were lysed by vigorous vortexing for 3
minutes. The lysate was then passed several times through a 2 1 G needle attached to a 3
ml syringe until all clumps were dissolved. The tubes were then centrifuged for 3
minutes at 1 600 rpm. The lysate was then transferred to a Lysate Clear Column and
centrifuged at 13 .000 rpm at RT for 3 minutes in order to reduce the viscosity of the
lysate. Fifty µl of Oligo (dt) magnetfoally labeled MicroBeads was added to the lysate
and hybridization with the poly (A) tail of the mRNA occurred. A MACS Column type µ
was placed on a magnetic stand and the column was washed with 1 00 µJ of Lysis/Binding
buffer. The lysate, was passed through the column and the magnetically labeled mRNA
was retained in the column. The column was washed several times with lysis/binding
buffer to remove any proteins and DNA, then with a wash buffer to remove any rRNA
and DNA. The mRNA was eluted with a 65 °C pre-heated elution buffer. Quantitation of
the mRNA was done on a spectrophotometer using OD260.
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cDNA Synthesis
mRNA was synthesized into first strand cDNA using the Superscript™ First-Strand
Synthesis System for RT-PCR by Life Technologies (Carlsbad, CA) according to
protocol. A gene specific primer (5' GCCAAGCACACGAGGGTAGCC 3') which
binds to the constant region of the beta chain (Cf3) of the T cell receptor was used for
cDNA synthesis. 1 mM Cl3 primer was mixed with 100 ng of mRNA 10 mM dNTP mix,
and DEPC-treated water then incubated at 65 °C for 5 minutes, then 4 °C for 3 minutes.
Each RNA/primer mixture then received 2 µl 10 X buffer, 4 µl 25 mM MgCh, 2 µl 0.1 M
DTT, 1 µl RnaseOUT RNase inhibitor, and the tubes were incubated at 42 °C for 2
minutes. Next, 1 µl (50 units) of Superscript n™ reverse transcriptase enzyme was
added to each tube and incubated for 50 minutes at 42 ° C. The reactions were terminated
at 70°C for 15 minutes, then chilled at 4 °C. I µl RNaseH was added to each tube and
incubation was 20 minutes at 37°C.

RT-PCR
The primers used for reverse transcriptase polymerase chain reaction (RT-PCR) and
cDNA synthesis were generated based on previous work done by L. Steinman (4) and
were purchased from Life Technologies (Carlsbad, CA). Each of the nineteen primers is
specific for a different variable region sequence of the beta chain (Vl3) of the TCR. The
sequences of the primers can be found in Table 1 .
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Table 1 : TCR VB primers

Tm

Primer

Sequence

V'3 l :
V�2:
VJ33 :
V/34:
V'35. l :
V'36:
VJ37:
V'38:
Vf39:
V'3 I0:
V�l l :
V'3 1 2:
V'3 1 3 :
V'314:
V'3 1 5 :
V�l6:
VJ3 l 7:
VJ31 8:
Vf3 19:
C'3:

5' ATC TAA TCC TGG GAA GAG CAA AT
S' GGC GTC TGG TAC CAC GTG GTC AA
5' GTG AAA GGG CAA GGA CAA AAA GC
5' GAT ATG CGA ACA GTA TCT AGG C
5' ACA TAA CA AAG GAA AGG GAG AA
5' TCC TGA TTG GTC AGG AAG GGC AA
5' TAC CTG ATC AAA AGA ATG GGA GA
5' GTA CTG GTA TCG GCA GGA CAC
5 ' AGC TTG CAA GAG TTG GAA AAC CA
5' GAT TAT GTT TAG CTA CAA TAA TA
5' ACA AGG TGA CAG GGA AGG GAC AA
5' ACC TAC AGA ACC CAA GGA CTC AG
5 ' CAG TTG CCC TCG GAT CGA TIT TC
5' GCC GAG ATC AAG GCT GTG GGC AG
5 ' AGA ACC ATC TGT AAG AGT GGA AC
5' CAT CAA ATA ATA CAT ATG GGG CA
5' GTA GTC CTG AAA AGG GCA CAC T
5' CAT CTG TCA AAG TGG CAC TTC A
5 ' AGA CAT CTG GTC AAA GGA AAA G
5' GCC AAG CAC ACG AGG GTA GCC

3'
3'

3'
3'
3'
3'
3'
3'
3'
3'
3'
3'
3'
3'

3'
3'
3'
3'
3'
3'

47
56
50
48
45
52
47
51
48
39
52
52
52
57
48
4S

50
48
46
55

Each reaction included one ofthe nineteen Vf3 primers along with the Cf3 primer, 10 mM
dNTPs, water, lOX buffer, and Pfu TurboR DNA Polymerase (Stratagene, La Jolla, CA),
and cDNA. PCR reaction conditions were: an initial denaturing step of95°C for 2
minutes ( 1 cycle), followed by 25 cycles of denaturation, annealing, and extension at
95°C for 2 minutes, 55°C/65° C for 1 min, and 72 °C for 30 seconds, respectively, then, a
final extension step of72 °C for 7 minutes. PCR was carried out in a Thermocycler
(Eppendorf). RT-PCR products were separated on a 1 % agarose gel containing 5%
Ethidium Bromide (Sigma) in 1 X TBE (Trizma base, boric acid, EDTA) for
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approximately 30 minutes at 1 00 volts then viewed under UV light. A DNA ladder was
run along with each gel to designate the size of the unknown bands. From known
sequence data of TCRs, the derived PCR is of approximately 400 base pairs (bp ).

Electroelution of DNA

The 400 bp band was excised from the gel and placed in a DNA dialysis bag along with
~ 1 ml of 1 X TBE. The bag was placed back in the electrophoresis apparatus and the
DNA was electroeluted from the gel at 1 00 Volts for ~30 minutes. The buffer containing
the DNA was removed from the bag, put into microfuge tubes. The DNA was ethanol
precipitated with 1/10 v/v 3M sodium acetate pH 5.2, and 2 X v/v 100% ice-cold ethanol.
The tubes were spun for 30 minutes at 1 4,000 rpm at 4° C. The supernatant was decanted,
and the pellet dried then resuspended in 100 µI DEPC treated water and stored at -20 °C
until further use.

Nucleotide Sequencing

DNA sequencing was performed by the UTK Molecular Biology Resource Facility.
Sequencing reactions (20 ul) we performed with purified PCR fragments (~30 ng)
according to the directions supplied with the Big Dye DNA Sequencing Kit (Applied
Biosystems, Foster City, CA). Reaction products were purified by Sephadex G50

chromatography with CentriSep columns (Princeton Separations, Adelphia, NJ) and
resuspended in 15 ul ultrapure deionized formamide (Applied Biosystems). Purified
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sequencing reaction products were electrophoresed and analyzed using a capillary
electrophoresis instrument (Model 3 100, Applied Biosystems).

Sequencing Analysis

Nucleotide sequences were entered into the NCBI (National Center for Biotechnology
Information) Blast search database in order to match with homologous sequences and
identify the variable (V), joining (J), and constant (C) regions
(http:www.ncbi.nlm.nih.gov). A second search engine, the Immunogenetics V-Query
and Standardization (IMGTN Quest), was also used to characterize the TCRs. The
IMGTN Quest is an alignment too] designed specifica11y for the alignment of TCR and
lg nucleotide sequences, (http://imgt.cines. fr: 8104). The database aligned the nucleotide
sequences of the splenic and lymph node TCRs with those in the IMGTN Quest
reference directory sets, thus identifying the V, D, and J regions by giving a score based
on the amount of homology. Additionally, the IMGTN Quest identified the CDR3
regions of rearranged V-D-J genes extending from the amino acid following the
conserved Cysteine at position 104 in the variable region to, but not including, the
phenylalanine or tryptophan in the joining region.
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ID. RESULTS
Prior investigations in our laboratory have demonstrated that SJL/J mice given Ig
PLP l in saline on the day of birth and challenged with PLPI peptide in CFA at the age of
7 weeks develop an organ specific T cell responses characterized by a deviation in the
lymph node and an a novel form of anergy in the spleen (2 1 ). Table 2 summarizes these
results and shows that the response against PLP I peptide in the control mice given Ig-W
at birth is a typical Th 1 type response in both the spleen and lymph node. However, in the
test mice given lg-PLP l , the lymph node T cells proliferate and produce IL-4 instead of
IL-2 while in the spleen the cells do not proliferate, or produce IFNy but secret IL-2.
These splenic cells, however, regain the ability to proliferate and produce IFNy is assisted
with exogenous IL-12 or IFNy. Therefore, the splenic T ce11s were defined as anergic,
and since the response can be restored by IFNy, we termed this novel form of anergy as
IFNy-dependent anergy. This observation prompted us to investigate whether reactivity
of the T cell receptor to PLP I peptide plays a role in the organ specific response in these
mice. As the T cell receptor is membrane bound protein and measurement of affinity is
not feasible we sought to immortalize cells from both organs and determine the structure
of the T ce1l receptors. VariabiJity within the CDR3 region of the T ce1l receptor 13 chain
will be indicative of differing affinity and could provide information on whether antigen
reactivity is responsible for the organ specific responses. To address this issue, T cells
lines were generated from both the lymph node and the spleen of Ig-PLP 1 tolerized and
PLP I peptide immunized mice and immortalized by fusion with a thymoma cell line.
Then their T cell receptor was cloned, sequenced, and analysed.
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Table 2. Summary of the Lymph Node and Splenic Responses to PLPl Peptide in
Mice Recipient of Ig-PLPl or Ig-W at Birth.
Injection
at birth

Proliferation

Cytokine
Production

Response
Status

A. Splenic response

yes

lg-W
Ig-PLP l

No, but can
be restored by
exogenous IFN-y
or IL-1 2 in vitro
or IL-1 2 in vivo

IL-2,

IFN-y

only IL-2, but
IFN-y production
can be restored
by exogenous
IL-1 2 in vitro

standard
unusual IFN-y
mediated anergy

B. Lymph node response

Ig-W

yes

Ig-PLPl

yes

IL-2

standard

IL-4

IL-4 driven T
cell deviation

Generation of T Cell Hybridoma Clones

SJL/J mouse pups were tolerized on the day of birth with 1 00 µg Ig-PLP l in
saline and when the mice reached the age of 6 to 8 weeks they were immunized with 1 00
µg PLP 1 peptide in CFA/ PBS (1 : 1 v/v). Ten days later, the mice were euthanized, their
spleens and lymph nodes removed, and separate T cell lines were generated from each
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organ. In order to expand the PLP 1 specific T cell populations, the T cell lines
underwent at least three cycles of resting and restimulation. Resting conditions consisted
of incubating the cells in media containing 3% T-stim for 7- 10 days, while restimulation
conditions consisted of incubating with PLPl peptide ( 1 5 µg/ml), APCs (2 x 1 06/ml) and
T-stim (3%). In addition, the splenic T cell lines received exogeneous IL- 1 2 in order to
restore their nonproliferative state. Once the T cell lines were established, the cells were
immortalized by being fused with a mouse thymoma cell line, BWl 1 00 which is deficient
for the TCR a.� chains as described in materials and methods. The hybridomas were then
cloned by limiting dilution to obtain a homogeneous population for T cell receptor
analyses.
Screening of Splenic T Cell Hybridomas
Five T cell hybridoma clones, SP 5D9#4, SP3A1# 1 1 , SP 4D1#3, SP 6E7#1 0, and SP
10E5#6, were generated from the spleen and tested for the production ofIFN-y.
Production of IFNy by the clones upon stimulation with PLPl but not PLP2 peptide
indicated that the cells have recovered from splenic anergy and are representative of the
splenic response (Figure 5). All five clones were generated from separate mice and
produced different amounts of IFN-y (Figure 5). These clones will be used to clone the T
cell receptor VP gene and determine the structure of the third hypervariable region to
correlate antigen specificity with migration to the spleen.
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900
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PLPl
f-------------4 ■ PLP2 .,__,____---1

Figure 5: Representative PLPl-Specific Splenic T Cell Hybridomas ·

T cell hybridoma clones generated from the spleens of Ig-PLPl tolerized, PLPl
immunized mice produce IFN-y upon stimulation with PLP l peptide and syngenic APCs.
Stimulation with the negative control, PLP2 peptide, instead of PLPl , did not induce any
detectable IFN-y.
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Determination of Cell Surface T.CR 6 Chain Expression on the Splenic T Cell
Hybridomas by Flow Cytometry
The representative splenic T cell hybridoma clones were stained with a panel of
FITC labeled monoclonal antibodies specific for different variable regions of the beta
chain of the TCR. The panel included mAbs against Vf32, Vf33, V{34, Vf35. l/5.2, Vf36,
VP7, Vp8. 1/8.2, Vp8.3, Vp9, vp 1 0, VP l l , VP 12, VP 13, VP 14, or VP 17. PE labeled
anti-CD4 mAb was also included to identify the clones as helper T cells. A total of
nineteen Vl3 regions are known, however, only fourteen of the nineteen have mAbs
available for flow cytometry, the exceptions being Vf H , Vf3 1 5, Vf3 16, Vf3 1 8, and Vf3 1 9.
Therefore, two control mAbs, one which binds to the CD3 protein and one which binds to
the constant region of the TCR f3 chain, were included in order to ensure that the TCR
was present on the clones. Figure 6 depicts the dot plots generated from one splenic
hybridoma clone, SP 5D9#4. Each dot plot represents staining with a different anti-Vf3
plus anti-CD4. Quadrants on the dot plots were set based on the FLl and FL2 values of
the unstained cells. The lower left quadrant is considered double negative, the upper left
single positive for the PE labeled mAb (aCD4), the lower right single positive the FITC
labeled mAb (aVf3 ), and the upper right as double positive. SP 5D9#4 stained double
positive for CD4 and V'37 as seen in figure 6. This clone was positive exclusively for
Vf37 since all other histograms showed only a single positive staining for CD4. The
controls for SP 5D9#4 also indicated that the clone was positive for CD3 and the TCR 13
chain constant region. A second splenic hybridoma clone, SP 6E7# 10 also stained
positive for vr, 7 as well as the controls (Figure 7). Three other clones SP 3A 1 # 1 1 , SP
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Figure 6: Prototype Flow Cytometry Analysis of the TCR f3 Chain Expressed on the Splenic T Cell
Bybridoma SP 5D9.#4
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Figure 6 Continued: Prototype Flow Cytometry Analysis of the TCR f3 Chain Expressed on the Splenic T
Cell Hybridoma SP 5D9 #4
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Figure 7: TCR P Chain Expression on Splenic T Cell Hybridomas
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1 0E5#6, & SP 4D1 #3 did not stain positive with any of the V(3 mAb (Fi gure 7).
However, all three stained positive for CD3, CD4, and the TCR (3 chain (Fi gure 7).
Therefore, the V(3 used in these three clones could be either V(3 1 , V(3 1 5, V(3 16, V(3 1 8, or
V(3 1 9 which will be determined later by RT-PCR.

RT-PCR & Sequencing Analyses of Splenic T Cell Hybridomas

For further investigations of the TCRs on the splenic hybridoma clones, molecular
analyses were performed. Messenger RNA was extracted from each of the clones,
followed by synthesis of cDNA. Then, PCR amplification was performed using primers
specific for nineteen different variable regions of the TCR beta chain along with a primer
specific for the constant region (4 ). Each PCR reaction included a different V� primer
along with the cp primer. From known TCR sequences, it was estimated that the PCR
fragment of interest was approximately 400 nucleotide base pairs (bp). In order to
visualize the amplified DNA, the gel was stained with ethidium bromide by performing
electrophoresis in buffer supplemented with with ethidium bromide. For the splenic T
cell hybridoma clone SP 5D9#4� a band in the gel of around 400 bp was observed when
primers V(37 and C(3 were used (Figure 8). The gel confirmed that the clone contained
only one Vb since the other primer combinations did not yield any product (Figure 8). A
control cell line with a known TCR V(36 usage was included using the V(36 and C(3
primers, and a band was observed in the respective lane of the gel. PCR analyses of the
clone SP 6E7# 10 also gave a band of the correct size when V(3 7 and C(3 primers were
used. Therefore, the PCR analyses confirmed the flow cytometry data for
37

�400 bp

Figure 8: Identification of TCR VP Usage of SP 5D9#4 by RT-PCR
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the clones SP 5D9#4 and SP 6E7# 10. For the other three clones, which did not stain with
any of the available anti-V'3 antibodies, the V'3 usage was identified by RT-PCR. For SP
I 0E5#6 and SP 4D 1#3 a TCR V'3 band was obtained with V'3 l6 primer, while SP
3Al# l l generated a band with the appropriate size when V'3 l primer was used. The 400
bp fragments generated from the PCR reactions of each clone were excised from the gel,
extracted by electroelution, and subjected to nucleotide sequencing (Figure 9). The
nucleotide sequences were subject to comparisons with sequences of known TCRs using
the BLAST search and the IMGTN Quest databases in order to identify the variable,
diversity, and joining regions. The clones were found to contain the following gene
segments:
SP 5D9#4
SP3Al# l l
SP 4D1#3
SP 6E7# 1 0
SP 1 0E5#6

Vf37 Df3 Jf3 1.5 Cf3
V'3 l D'3 J'32.5 C'3
V�l6 D� J�l .4 C�
V'37 D'3 J'32.3 C'3
Vl} 16 DP Jl}2.4 cp

Screening of Lymph Node T Cell Hybridomas
From the lymph nodes of the same Ig-PLP I tolerized mice, five T cell hybridoma
clones, LN 3E6.B8.G8, LN 6F6.Al , LN 20F7.F3.A3, LN 3 1 G5.B12, and LN 22B6.G7,
were generated as described above. These clones were screened for their production of
IL-4 in order to ensure that the clones were representative of those cells which underwent
a Th2 type immune deviation in vivo. All five clones produced various amounts of 1L-4
upon stimulation with PLPl peptide (Figure 10). Cytokine production by the T cells was
antigen specific since no IL-4 was detected when the control peptide, PLP2, was used for
39

Clone

Vfl

Dfi

Jfi

Cfi

SP 5D9#4: TGTGCTAGCAGTTCGGGGGCGCAAGGTCAGGCTCAGCATTTTGGAGAGGGGACTCGACTCTCTGTTCTAGAGGATCTGAGA
SP 6E7#10: . . . . . . . . . . . . C . TC . CCT . . CTA . . GCA . AAAC . . TG . A . TIT . GCTCA . GAACCAGACTGAC.G .TCTC. AGGA .CTG

SP 4D1#3: TGTGCCAGCAGCCCTACAGGTCTTTCCAACGAAAGCATTATTTTTCGGTACATGGAACCAAGCTGTCTGTCCTGGAGGA
SP 10E5#6: . . . . . . . . . . . GGAC . GTCAAAACA . . TTGT . CTTTGG . GCGGGCACCCGAC.ATCGGTGCTAGAGGATCTGAGAAA
SP 3A1#11: TGTGCCAGCAGCCAAGTATTCCCCTGGGGGGTGACACCCAGTACTCTTGGGCCAGCGCACTCGGCTGCCTCGTGTTAGAGG

0
�

Figure 9: Partial Nucleotide Sequences of the TCR f3 Chain of Splenic T Cell Hybridoma Clones

Dots represent base similarity
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Figure 10: IL-4 Production by Lymph Node T Cell Hybridomas
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stimulation.

Flow Cytometry Analyses of Lymph Node T Cell Hybridomas

The lymph node hybridoma cells were analyzed by flow cytometry for their TCR
Vf3 usage in the same fashion as the splenic hybriomas. Briefly, the cells were stained
with a panel ofFITC labeled mAb specific for different VJ3s and a PE labeled anti-CD4
mAb. The variable regions ofLN 3E6.B8.G8, LN 20F7.F3.A3, and LN 3 1 G5.B 1 2 were
identified as VJ34 while LN 22B6.G7 stained positive for VJ314, and LN 20F7.F3.A3 did
not stain positive for any of the available Vf3 mAbs (Figure 1 1 ). All five of the clones
stained positive for the controls, CD4, CD3, and TCR J3 chain (Figure 1 1).

RT-PCR & Sequencing Analyses of Lymph Node T Cell Hybridomas

To confirm the flow cytometry data and to obtain TCR sequences of the clones,
RT-PCR was performed on the lymph node T cell hybridoma as described for the splenic

clones. Briefly, a common primer for the constant region of the beta chain (C�) was used
along with nineteen primers pertaining to the different variable regions of the beta chain
(V� ). The bands generated from the PCR reactions were excised from the agarose gel
and sequenced (Figure 1 2). Analysis of the nucleotide sequencing data identified the
gene segments for the lymph node clones as:
LN 3 1 G5.B 1 2
LN 20F7.A3
LN 22B6.G7
LN 6F6.Al
LN 3E6.G8

vp4 np2 1p2.6 cp

VJ34 DJ32 JJ32. 7 CJ3
V�16 D� J�2.4 C�
VJ3 14 D132 Jf32. 1 CJ3

vp4 np2 1p2.s cp
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Figure 11: TCR � Chain Expression on Lymph Node T Cell
Hybridomas
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Clone
LN 20F7.A3:

LN 31G5.B12:
LN 3E6.G8:

�
�

Vil

Dfi

N

Jfi

Cfi

TGTGCCAGCAGCCAGACTGGGGGGGCGAGGGGTGAGCAGTACTICGGTCCTGGCACCAGGCTCACGGTTTTAGAGGAT
. . . . . . . . . . . . AGACTG . . . . . . CGAG . . . TGAGCAGTACT . CG . TC . TG. CAC . AGGCTCACG. T . . . AGAG . AT
. . . . . . . . . . . . . . CT . . . . . . . ACGAGACACCCAGTACT. TGGG. CAGG . ACTNGG. TAC. . NGT. T . TGAG. . T

LN 6F6.A1 :

TGTGCCTGGAGCCCTCTGGGGGGCCCTGCTGAGCAGTICTTCGGACCAGGGACACGACTCACCGTCCTAGAGGATC

LN 22B6.G7:

TGTGCCAGCAGCGGAGGCACATCAAATCACAACCCCTTIGTACTGTGGTGCGGGCACCTTACTATAGGAGCTAGAGGA

Figure 12: Partial nucleotide sequences of the TCR p chain of Lymph Node T Cell Hybridomas

Dots represent base similarity

Summary of VB, DB and JB Usage of Splenic and Lymph Node Hybridomas
Limited heterogeneity was seen in the VJ3 usage within and between the spleen
and lymph node T cell clones (Figure 13). Two out ofthe 5 splenic clones used VJ37,
while another 2 used VJ3 l 6, and only one used Vf3 l . Meanwhile, three ofthe five lymph
node clones used VJ34, one used VJ3 16, and another used VJ3 14.

In comparing the VJ3

usage between the two organs, the clones from the spleen used predominantly VJ3 7 and
VJ3 16, whereas the lymph node cells used predominantely VJ34. However, there seemed
to be no specific restriction in the VJ3 usage between or within the splenic and lymph
node T cells.
The JJ3 usage was also heterogeneous within and between the two organs. Out of
five clones generated from the spleen, five different JJ3s were used: JJ3 1. 4, JJ3 1.5, JJ32.3,
JJ32. 4, JJ32.5. Ofthe five lymph node clones, five various JJ3s were also seen: Jf32. 1,
JJ32.4, JJ32.5, JJ32.6, JJ32.7.
While there seemed to be no restriction in the V or J usage in either organ, an
interesting discovery was made when the DJ3 usage was compared between the two
organs. As mentioned previously, each TCR sequence was subject to analysis by the
IMGTN Quest database alignment tool for TCR and Ig nucleotide sequences (Marie

Paule Lefranc, Montpellier, France (http://imgt.cines.fr:8104)). The database serves to
aJign unknown sequences with sequences in their database of known TCRs. Scores are
given based on the similarity rate in comparison with known sequences. When the TCR
sequences from the lymph node T cells were entered into the database, it was found that
four out of five showed a higher alignment score with 0�2 than with D� 1 while the
45

Clone
LN 3E6.G8
LN 31G5.B12
LN 20F7.A3
LN 6F6.Al
LN 22B6.G7
SP 5D9#4
SP 6E7#10
SP3Al#l l
SP 4Dl#3
SP 10E5#6

V(3

D(3

VJ34
VJ34
VJ34
VJ3 14
VJ3 16
VJ37
VJ37
VJ3 1
VJ3 16
VJ3 1 6

DJ32
DJ32
DJ32
DJ32
DJ3

JJ32.5
JJ32.6
JJ32.7
Jf32.1
JJ32.4

DJ3
DJ3
DJ3
DJ3
DJ3

JJ3 1.5
JJ32.3
Jf32.5
JJ3 1.4
JJ32.4

Figure 13: Comparision of Variable (V), Diversity (D), and Joining (J)
Segments of Splenic and Lymph Node T_ Cell Hybridoma Clones from
lg-PLPl Tolerized Mice
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remaining one showed an equal score with both (Figure 1 4). However, in the spleen, 3
out of five did not align with either DJ3 l or DJ32 while the other two aligned equally with
both DJ3 l and Df32. Additionally, in the clones from the lymph node, the DJ3 regions
showed a high degree of homology between each other whereas the clones from the
spleen did not seem to exhibit any homology (Figure 1 5). Therefore, it can be concluded
that clones from the lymph node show a preferred usage of DJ32, while the clones from
the spleen have an undetermined Df3 usage.

Comparison of the TCRB CDR3 regions of Splenic and Lymph Node Hybridomas
The CDR3 has been defined as the most influential element in the formation of
the antigen binding site and thereby specificity as well as affinity of the TCR to antigen.
Thus, for comparison of the antigen binding region between the splenic and lymph node
clones, the nucleotide sequences were translated to the corresponding amino acid
sequences and the CDR3 regions were examined. The beta chain CDR3 region was
identified according to the IMGTN Quest database (http://imgt.cines.fr:8104). In the
lymph node, all five clones showed a CDR3 length of between 11-13 amino acids, while
in the spleen the lengths of the CDR3 regions appeared to be between 10-13 amino acids
in length in 4 out of 5 clones (Figure 16). The length of the other splenic clone could not
be determined via this analysis. Accordingly, the lengths of the CDR3 regions, when
compared between the lymph node and splenic clones, were found to be similar.
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DB Region Alignment Scores
Clone
LN 3E6.B8.G8
LN 31G5.B12
LN 20F7.F3.A3
LN 6F6.Al
LN 22B6.G7
SP 5D9#4
SP3Al#1 1
SP 4D1#3
SP 6E7#10
SP 10E5#6

opt
+
+
+
+

+/-

+/-

+/

+/

+/-

+/-

Figure14: DP Region Alignment Scores from Splenic and Lymph Node
Hybridomas

+ indicates maximal homology with indicated DJ3 family
- indicates lower homology with indicated Df3 family
+/- indicates equal homology with both DJ3 l and DJ32 families
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D Region

Clone
LN 20F7.F3.A3:
LN 6F6.Al :
LN 3E6.B8.G8:
LN 31G5.B12:
LN 22B6.G7:

SP 3Al#l l :
SP 5D9#4:
SP 6E7#10:
SP 4D1#3:

CAGACTGGGGGGGC GAGGGGT
CCT • . • . . • • •
CACT . • • . • • . .
AGA • . • . • • • • . .
GGAGGCACATC

CAAGTATTCCC

CTGGGGGG
TC • • • • • • CGCAAGGT
CC. C • CCT . CCTAG
AGCCC. ACA . •TC
SP 10E5#6:
AGGGAC

Figure 15: Comparison of DP Regions for Maximum Similarity

Dots represent identical bases
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Oone

Vl
0

VB

JI!

CDR3

LN 6F6A.1 :

TGT
C

GCC TGG AGC CCT CTG GGG GGC CCT GCT GAG CAG
A W
S
P
L
G G
P
A E
Q

TTC TTC GGA CCA GGG
F
F
G
P
G

LN 3E6.88.G8:

TGT
C

GCC AGC AGC CAC TCT GGG GGA CGA GAC ACC CAG TAC
A S
S H
S
G
G
R D T
Q
Y

TIT GGG CCA GGC
F
P
G
G

LN 20F7.F3A.3:

TGT
C

GCC AGC AGC CAG ACT GGG GGG GCG AGG GGT GAG CAG TAC
R G E
Q
Y
S
Q
T
G G A
A S

TIC GGT CCT GGC
P
F G
G

LN 31 G5.B12:

TGT
C

GCC AGC AGC AGA CTG GGG GGG CGA GGG GTG AGC AGT
A S
S
R L
G
G
R
G
V
S
S

ACT TCG GTC CTG GCA
T S
V
L A

LN 22B6.G7:

TGT
C

GCC AGC AGC GGA GGC ACA TCA AAT CAC AAC CCC TTG
A S
S
G
G T
S N H
N
P
L

TAC TGT GGT GCG GGC
Y
C
G
A
G

SP 5D9#4:

TGT
C

GCT AGC AGT TCG GGG GCG CAA GGT CAG GCT CAG CAT
A S
S S
G
A
Q
G Q
A Q
H

TIT GGA GAG GGG
F
E
G
G

SP 6E7#10:

TGT
C

GCT AGC AGT ccr CGC CTG CCT AGT GCA GAA ACG CTG TAT
A S
S P R L P S A E T L Y

TTT GGC TCA GGA
F
S
G
G

SP 4D1#3:

TGT
C

GCC AGC AGC ccr ACA GGT CTI TCC AAC GAA AGC ATT ATT
A S
S
P T G L
S
N E
S
I
I

TTT CGG TAC ATG
F
R
Y M

SP 10E5#6:

TGT
C

GCC AGC AGG GAC AGT CAA AAC ACC TTG TAC
A S
R D
S Q
N
T
L Y

TTT GGT GCG GGC
F
G
A
G

SP 3Al#l l :

TGT
C

GCC AGC AGC CAA GTA TIC CCC TGG GGG GTG ACA CCC AGT ACT CTI GGG CCA GCG
A S
S
Q
V
F P
W G
V T
P
S
T
L
G
P
A

Figure 16: Comparision of the CDR3 Regions of Lymph Node and Splenic T Cell Clones from Neonatally Tolerized Mice

However, the most exciting discovery was made when comparing the amino acid
sequences between the splenic and lymph node clones. In the lymph node, all five clones
generated contained a Glycine-Glycine motif (Figure 1 6). Furthermore, this motif was
absent in the clones generated from the spleen (Figure 16).
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IV. DISCUSSION
Previously, it was shown that SJL/J mice given Ig-PLP l in saline at the neonatal
stage were resistant to the induction of Experimental Allergic Encephalitomyelitis (EAE)
later in life (21 ). Contributing to this resistance were T cells which displayed a unique
phenotype consisting of IFN-y mediated anergy in the spleen, and Th2 deviation in the
lymph nodes (Table 1) (21). The objective of these studies was to investigate whether
differences in the T cell repertoires between the lymph node and spleen contributed to
this organ specific modulation of disease. This was achieved by immortalizing PLP 1
specific T cell hybridomas from both lymphoid organs and analyzing their T cell
receptors. Specifically, the T cell receptor beta chains were analyzed for their variable
(V), diversity (D), andjoining (J) gene segment usage to see whether or not a particular

gene segment may be involved in the responses. Additionally, the CDR3 regions were
analyzed by their lengths and amino acid composition to gain further insight about the
antigen- binding site.
The most important finding was seen when analyzing the CDR3 regions of the
TCRs from the lymph nodes and spleens ofig-PLPI tolerized, PLPI immunized mice. A
common Gly-Gly motif was found in the TCR sequences of the T cells obtained from the
lymph node. The splenic T cells did not contain this motif, but rather displayed random

combinations of amino acids. Glycine is the smallest amino acid, containing only a
hydrogen atom for a side chain. Thus, when two glycines are next to each other in a
protein sequence, it is likely that bending will occur due to the lack of interactions with
bulky side chains. It has been proposed that glycines promote bending of the TCR and
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this flexibility may be important for antigen binding (26). It is common that glycines in a
loop region will cause a bend or tum and in fact, the CDR3 is in a loop region.
Therefore, it could be assumed that the GJy-Gly motif found in the CDR3 regions of the
lymph node cells could create a bend in the loop which may affect the TCR binding to
the antigen. Furthermore, since the Gly-Gly motif was not found in any of the TCR
sequences of the splenic cells and these cells displayed a different phenotype than the
lymph node cells, it could be postulated that the cells from the two organs interact with
the antigen with different strength or affinity.
Recent advances have provided major insights into the structural basis of antigen
binding by the TCR. The majority of this information was gained by the elucidation of
the crystal structure of the af3 TCR heterodimer alone and in association with a peptide
MHC complex ( I 0). Structurally the TCR is similar to an immunoglobulin molecule,
containing globular motifs consisting of layers of f3-pleated sheets, and three
complementarity determining regions (CDRs) in the form of exposed loops which
interact with the peptide-Ml-IC complex. The heterodimer consists of the a and f3 chains,
and each chain contains a variable and constant domain. The Va domain is thought to
steer the TCR for proper docking orientation over the peptide-MI-IC, while the Vf3
domain positions and are unique in each structure. In the af3 heterodimer, CDR1 and
CDR2 are considered to be structurally similar in most TCRs and interact mainly with
MHC structural elements. Meanwhile, the CDR3 regions have predominant contact with
the peptide causing them to have a higher sequence diversity and length and therefore
undergo substantially different conformations in each TCR structure ( 1 0). Poor shape
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complementarity between the peptide and TCR CDR3 regions facilitates the TCR' s
ability to adapt to different bound ligands with different biological outcomes ( 1 0).
As mentioned above, it is still unclear as to what the structure of the CDR3
regions of a particular TCR are, due to the high variability of each unique TCR.
Computational protein modeling can be used to construct a 3-D image of TCRs (29).
Homology modeling is one such tool and is achieved by entering the amino acid
sequence of a query protein into a computer database, such as SWISS-MODEL
(www.expasy.ch/swissmod/SWISS-MODEL.html). SWISS-MODEL can predict a
structure by constructing the coordinates ofthe atoms based on sequence alignment
between the query protein and a known protein structure from the protein structure
database (PDB) (29). For a reliable model, a high sequence identity between a query
protein and its template in the protein structure database is necessary. Since the 3-D
structure of other TCRs have been substantially elucidated by crystallography, and our
nucleotide sequencing data has identified our sequences as TCRs, our proteins were
prime candidates for such modeling. Therefore, sequences of two representative clones,
one from the spleen and one from the lymph node, were submitted to the SWISS
MODEL automated server, and models of each of the proteins were generated.
Figure 1 7 depicts a model of how one TCR Vf3 from the lymph node ( 1 7a.) might fold
compared with one TCR V� from the spleen ( 17b. ). The lymph node TCR contains a
more rigid loop, whereas the splenic TCR contains a more round contact area. Since it is
known that the CDR3 region has direct contact with the peptide, the shape ofthis area
would have a direct effect on peptide binding.
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Since it is evident that the TCRs from the cells isolated from the lymph nodes are
structurally different from those in the spleen, it can be assumed that the TCRs from the
different organs will bind the antigen with different affinities. While the model structures
generated in figure 17 are useful in seeing the structure of the TCRs, a better visual
would

be of the entire TCR a.'3 heterdimer complexed with the PLP 1 and WICII

molecule. This would elucidate whether or not the glycines are contact residues and what
involvement they have in the antigen binding. This would require more complex protein
modeling databases or generating a crystal structure either of which are out of the scope
of these experiments. Of course, to elicit the complete structures of the TCRs from the
clones, crystallography can be performed.
When first analyzing the TCR structures, it would appear as though the more rigid
tum in the CDR3 region of the lymph node cells would lead to a tighter, more specific
binding. However, speculations can be made by comparisons with previously elucidated
TCR structures. The first murine TCR structure reported was that of the 2C TCR
complexed with its corresponding JMHC and peptide ( 1 1 ). Interestingly, the CDR3 J3
contained an unusually high number of glycines but had surprisingly minimal contact
with the peptide ( 10). If the Gly-Gly motif of the TCRs from the lymph node cells
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°'
V.

Figure 17: Tridementional Computer Model of the TCRJ3 chain from the Splenic T Cell Hybridoma SP 10E5#6 (A.) and the
Lymph Node Hybridoma, LN 3E6.B8.G8 (B.)
Homology modeling generated by SWISS-MODEL (www.expasy.ch/swissmod/SWISS-MODEL.html)
Blue region indicates CDRI loop, Purple CDR2 loop, and Yellow CDR3 loop
Gly-Gly motif in the lymph node clone is labeled (B.)

creates a rigid structure which also has minimal contact with the peptide, then it can be
assumed that the TCR will bind the peptide with a weaker affinity. If this is true, then it
would be in agreement with other systems which propose that weaker peptide binding
affinity leads to deviation toward a Th2 phenotype (7) (20).
While preliminary modeling data is useful, in order to answer the question of
whether or not the cells from the different organs bind the antigen with different

affinities, binding assays can be performed on the cells. This can be done by a
Radioreceptor Assay such as is described in Current Protocols in Immunology (12).
Basically, by using radiolabeled PLP 1 peptide and a column along with several dilutions
ofhybridoma cells, then measuring the amount ofradioactivity on a gamma counter. The
amount is compared with that ofa known concentration and calculations are performed to
determine the affinity ofthe peptide binding. Ifthere are differences between the splenic
and lymph node cells then the answer ofwhether or not one binds with higher affinity
will be clear. The kinetics of TCR binding to PLPl peptide can also be measure using
competitive binding assays with detection using surface plasmon resonance, a more
involved but more accurate approach ( 1 9). Binding assays would be a useful tool in
supporting the TCR data.
In these studies, it was shown the T cell repertoires differ when comparing
between the lymph nodes and spleens ofig-PLP l tolerized, PLP l immunized, SJL/J
mice. However� the TCR usage was not restricted to a single VP or JP in the repertoires
from either the spleen or the lymph nodes. In related studies ofneonatal tolerance,
Balb/c mice were given an injection ofhen egg lysozyme (HEL106-1 16) peptide emulsified
in IFA at the neonatal stage, then challenged with the peptide in CFA as adults (20). Then
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they followed what they referred to as the 'public' T cell clone, which was characterized
by a TCR gene rearrangement containing a V�8.2 variable region and J� 1.5 joining
region and pertained to the majority of the anti-HEL T cell response. This 'public' clone
was shown to be deleted or anergized, while the residual antigen specific T cells
remained responsive but were deviated to a Th2 phenotype. They speculated that the
different clones may interact with the peptide with different affinities. The ' public' clone
may have had a stronger affinity toward the peptide resulting in deletion/anergy, while
the residual cells had a weaker interaction with the peptide resulting in a Th2 deviation
(20). This same phenomenon may be true in our findings in that the clones from both
organs are PLP1 specific but may interact with the peptide with different affinities. It is
possible that the lymph node cells have a weaker interaction with the PLP1 peptide
resulting in a Th2 deviation, while a stronger affinity is seen with the splenic clones
which leads to their anergy. However, these differences in affinity are thought to be due
to the differences in protein structures not due to restriction from a particular V� or J�
gene segment.
The T cell response to PLP I in adult SJL/J mice is heterogeneous with cells
expressing TCR Vps 2,3,4,6,7, and1 4 (23). So, no ' public' clone is seen in the PLPl
system as is seen in the HEL system. Therefore, it is not surprising that SJL/J mice
tolerized with lg-PLP1 at the neonatal stage then immunized with PLP1 as adults, do not
exhibit restriction at the TCR Vf3 or Jf3 level. Furthermore, it has also been shown that
organ-specific secondary responses can occur with homogeneous TCR-transgenic T cells
( 1 8). This particular study closely resembles the Ig-PLPl tolerization system, but instead
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uses another lg-chimera molecule, Ig-OVA, which contains the OVA323 _33 9 peptide
genetically inserted into an lg molecule in the same fashion as lg-PLPl was generated
( 1 8). Ig-OVA was injected into neonatal Balb/c mice along with the adoptive transfer of
OVA specific T cells neonatal DO 1 1. 10/SCID mice. These DO 1 1 . 10/SCID mice are TCR
transgenic mice and therefore the T cells all contain the same Vf3 and Jf3 gene segments.
These T cells were adoptively transferred into neonatal Balbic recipients along with
injection of Ig-OVA in saline, then at age 7 weeks the recipient mice were challenged
with OVA peptide in CFA and their secondary responses were measured. The same
organ specific responses were seen with the lg-OVA system as was seen with Ig-PLPl
tolerization in SJL/J mice. Specifically, the T cells in the lymph node were deviated to a
Th2 phenotype and in the spleen the same IFN-y mediated anergy was seen. The
proliferative response was restored in the spleen by supplying exogeneous IL-1 2 or IFN-y
in the same manner as was seen in the Ig-PLPl system. However> this organ specific
regulation in the TCR T g system required transfer of a high number of neonatal
D01 1. 1 0/SCID T cells. Therefore, it was postulated that the frequency of T cells rather
than repertoire diversity is responsible for the organ specific modulation seen in the organ
specific responses. This could also hold true for tolerization with lg-PLPl , since the
frequencies PLP 1 specific T cells was previously shown to be high in SJL/J mice (3 ).
While no restriction was seen in the V� or J� usage, similarities were seen in the
DJ3 regions of the TCRs from the lymph node cells. Four out of five were identified as
D132 and showed distinct homology with one another. The T cells from the spleen did
not show any homology with one another and could not be distinguished as either D13 1 or
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D(32. The homology seen in the D(32 regions of the lymph node cells was considered
important since the D region ofthe TCR beta chain is the most variable gene segment and
is the most responsible for antigen binding. This is also the region which translates into
the portion of the protein containing the Gly-Gly motif seen in the lymph node cells.
In conclusion, SJL/J mice injected with Ig-PLPl in saline at the neonatal stage
then challenged with PLPl peptide in CFA as adults exhibit organ specific secondary
responses consisting of IFN-y mediated sp1enic anergy and Th2 type immune deviation in
the lymph nodes. In these studies, it was found that these organ specific responses could
be due to structural differences in the TCRs ofceJJs taken from the lymph node versus
those from the spleen. Although there was no particular restriction in the V(3 or J(3 usage
from either organ, the lymph node ce11s contained a glycine-glycine motifin their TCRs
which was not present in the TCRs of the splenic clones. This Gly-Gly motif created
changes in the CDR3 loop region which lead to contrasting TCR structures between the
splenic and lymph node clones. Differences in the structures of the TCRs could be
indicative of differences in the binding affinities of the TCRs toward the peptide in the
different organs. It could be speculated that this Gly-Gly motif in the lymph node created
such rigidity in the TCR structure that minimal contact was made with the peptide. This
minimal contact could lend to a lower binding affinity which could be responsible for the
Th2 type deviation. Therefore, it can be concluded that TCR structural differences
between the splenic and lymph node clones taken from Ig-PLP 1 tolerized, PLP 1
immunized mice play a role in the generation of organ specific secondary responses.
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